Drug Trial Radar · NCT05615818
Personalized Medicine for Advanced Biliary Cancer Patients
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Jul 18, 2024
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; National Cancer Institute, France; Cancer Research UK; Taiho Oncology, Inc.; Servier; Zymeworks BC Inc.; Accord Healthcare, Inc.; Pierre Fabre Medicament
- First posted
- Nov 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, during which a molecular profile of the patient's tumour will be obtained, and (ii) a randomised comparative trial in which patients with disease control after 4 cycles of standard treatment, and whose tumour harbours a targetable molecular alteration, will be randomised (2:1) to receive either a matched targeted therapy or to continue with the standard treatment.
Conditions
- Biliary Tract Neoplasms
Interventions
FutibatinibDrug
Dose 20 mg once a day (QD)
IvosidenibDrug
Dose 500 mg QD
ZanidatamabDrug
Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
TrastuzumabDrug
Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
NeratinibDrug
Dose: 240 mg QD (combination with trastuzumab)
EncorafenibDrug
Dose: 450 mg QD (Combination with binimetinib)
BinimetinibDrug
Dose: 45 mg twice a day (BID) (Combination with encorafenib)
NiraparibDrug
Dose: 200 mg QD or 300 mg QD
CisplatinDrug
Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
GemcitabineDrug
Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From randomisation to disease progression or death, up to 5 years.
Locations
69 sites in 3 countries. Site status is shown where the registry gives one.
Cliniques universitaires de Bruxelles - Hôpital Erasme ULB
Brussels, Belgium · Not yet recruiting
Cliniques universitaires Saint-Luc
Brussels, Belgium · Not yet recruiting
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, Belgium · Not yet recruiting
Universitair Ziekenhuis Leuven
Leuven, Belgium · Not yet recruiting
CHU Amiens Picardie
Amiens, France · Recruiting
CHU d'Angers
Angers, France · Recruiting
Institut de cancerologie de l'Ouest - Angers
Angers, France · Recruiting
Institut du Cancer Avignon Provence
Avignon, France · Recruiting
CHU de Besançon
Besançon, France · Recruiting
CHU de Bordeaux - Hôpital Haut-Leveque
Bordeaux, France · Not yet recruiting
Centre François Baclesse
Caen, France · Recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Recruiting
CHU Estaing de Clermont Ferrand
Clermont-Ferrand, France · Recruiting
APHP - Hopital Henri Mondor
Créteil, France · Recruiting
CHU de Dijon
Dijon, France · Recruiting
CHU Grenoble Alpes
Grenoble, France · Not yet recruiting
Groupe hospitalier mutaliste de Grenoble - Institut Daniel Hollard
Grenoble, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
CHU Lille
Lille, France · Recruiting
CHU Dupuytren
Limoges, France · Recruiting
Centre Leon Bérard
Lyon, France · Not yet recruiting
Clinique Privée Jean Mermoz
Lyon, France · Not yet recruiting
Hospices Civils de Lyon - Croix Rousse
Lyon, France · Recruiting
APHM - CHU La Timone
Marseille, France · Not yet recruiting
Hôpital Européen
Marseille, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
Institut de Cancer de Montpellier
Montpellier, France · Recruiting
CHU Nantes - Hôtel Dieu
Nantes, France · Not yet recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
APHP - Hôpital Beaujon
Paris, France · Recruiting
APHP - Hôpital Cochin
Paris, France · Recruiting
APHP - Hôpital Saint Antoine
Paris, France · Recruiting
Groupe Hospitalier Diaconesses Croix Saint-Simon
Paris, France · Not yet recruiting
Institute Mutualiste Montsouris
Paris, France · Recruiting
CH de Pau
Pau, France · Recruiting
CHU Poitiers
Poitiers, France · Recruiting
CH Cornouaille
Quimper, France · Recruiting
CHU de Reims
Reims, France · Recruiting
Institut Jean Godinot
Reims, France · Recruiting
Centre Eugène Marquis
Rennes, France · Recruiting
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.